Questions a plan sponsor actually asks.
What is Efavirenz, Emtricitabine and Tenofovir Disoproxil used for?
Efavirenz, Emtricitabine and Tenofovir Disoproxil is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor medication tracked in Medicare Part D.
Is there a generic for Efavirenz, Emtricitabine and Tenofovir Disoproxil?
Yes. 6 ANDAs filed at FDA, 6 generic manufacturers currently shipping.
How much does my plan pay for Efavirenz, Emtricitabine and Tenofovir Disoproxil?
Across 329 Part D plans, Efavirenz, Emtricitabine and Tenofovir Disoproxil averages $1.31/unit (NADAC). Lowest available: $1.31/unit. Highest in distribution: $1.31/unit.
Is Efavirenz, Emtricitabine and Tenofovir Disoproxil on the FDA shortage list?
No. Efavirenz, Emtricitabine and Tenofovir Disoproxil is not currently on the FDA Drug Shortage Database.
4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.